Advertisement

Effects of Anticoagulants on Thrombolysis Mediated by Tissue Plasminogen Activator in Experimental Thrombosis Model

  • Katsumi Nakagawa
  • Hajime Tsuji
  • Keizo Yamada
  • Mitsuru Yoneda
  • Osamu Takada
  • Yuka Yamada
  • Haruchika Masuda
  • Masashi Uno
  • Toshiyuki Tamagaki
  • Masahito Yamagami
  • Kazuharu Katoh
  • Katsumi Yamamoto
  • Kyoichiro Kobayashi
  • Shohei Sawada
  • Masao Nakagawa
Conference paper

Abstract

Tissue plasminogen activator (t-PA) is being used as thrombolytic therapy for patients with acute myocardial infarction [1], given in combination with anticoagulants such as heparin or warfarin. We compared the effects of the new selective thrombin inhibitors, argatroban and hirudin, with those of heparin, on the thrombolysis mediated by t-PA in an experimental model of thrombosis using the hamster cheek pouch.

Keywords

Thrombolytic Therapy Subclavian Artery Tissue Plasminogen Activator Unfractionated Heparin Fibrinolytic System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Marder VJ, Sherry S. (1988) Thrombolytic therapy: current status. N Engl Med 318: 1512–1520CrossRefGoogle Scholar
  2. 2.
    Shanberge JN, Tsuji H, Longe TQ. (1990) Production of thrombi on intact endothelium by use of antiheparins in vivo. J Lab Clin Med 116: 831–839PubMedGoogle Scholar
  3. 3.
    Ik-Kyung Jang, Herman K. Gold, Robert C. Leinbach, John T. Fallon and Desire Collen. (1990) In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ Res 67: 1552–1561PubMedCrossRefGoogle Scholar
  4. 4.
    Gaffney PJ, Marsh NA, Thomas DP. (1982) The influence of heparin and heparin-like substances on the fibrinolytic system in vivo. Heamostasis 12: 85Google Scholar
  5. 5.
    Okamoto S, Hijikata A. (1981) Potent inhibition of thrombin by the newly synthesized arginine derivative No.805. The importance of stereostructure of its hydrophobic carboxamide portion. Biochem Biophy Res Commun 101: 440–446CrossRefGoogle Scholar
  6. 6.
    Rosenberg RD. Heparin-antithrombin system. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Colman RW, Hirsch J, Marder VJ, Salzman EW (eds). JP Lippincott, Philadelphia, PA 1987; pp 962–85Google Scholar
  7. 7.
    Tamao Y, Yamamoto T, Kikumoto R, Hara H, Itoh J, Hirata T, Mineo K, Okamoto S. (1986) Effect of a selective thrombin inhibitor MCI-9038 on fibrinolysis in vitro and in vivo. Thromb Heamostas 56: 29–34Google Scholar
  8. 8.
    Gorog P, Ridler CD, Kovacs IB. (1990) Heparin inhibits spontaneous thrombolysis and thrombolytic effect of both streptokinase and tissue-type plasminogen activator. An in vitro study of the dislodgement of platelet-rich thrombi formed from native blood. J Int Med 227: 125–132CrossRefGoogle Scholar
  9. 9.
    Heras M, Chesebro JH, Penny WJ Bailey KR, Badimon L, Fuster V. (1989) Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 79: 657–665PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 1993

Authors and Affiliations

  • Katsumi Nakagawa
    • 1
  • Hajime Tsuji
    • 1
  • Keizo Yamada
    • 1
  • Mitsuru Yoneda
    • 1
  • Osamu Takada
    • 1
  • Yuka Yamada
    • 1
  • Haruchika Masuda
    • 1
  • Masashi Uno
    • 1
  • Toshiyuki Tamagaki
    • 1
  • Masahito Yamagami
    • 1
  • Kazuharu Katoh
    • 1
  • Katsumi Yamamoto
    • 1
  • Kyoichiro Kobayashi
    • 1
  • Shohei Sawada
    • 1
  • Masao Nakagawa
    • 1
  1. 1.Second Department of MedicineKyoto Prefectural University of MedicineKamigyo-ku, Kyoto 602Japan

Personalised recommendations